anti-TIGIT mAb

Anti-TIGIT monoclonal antibodies (mAbs) are a class of immune checkpoint inhibitors designed to target the T-cell immunoreceptor with Ig and ITIM domains (TIGIT). TIGIT is a co-inhibitory receptor expressed on CD8+ T cells, Natural Killer (NK) cells, and regulatory T cells (Tregs). It competes with the activating receptor CD226 for binding to ligands such as CD155 (PVR) and CD112 (PVRL2) on tumor cells and antigen-presenting cells. By blocking the TIGIT pathway, these antibodies restore the effector functions of T and NK cells and enhance anti-tumor immunity. Furthermore, many anti-TIGIT mAbs, such as those developed by iTeos Therapeutics, are engineered with functional Fc regions to induce the depletion of intratumoral Tregs via Fc gamma receptor (FcγR) engagement, further alleviating immunosuppression in the tumor microenvironment. This class is widely investigated in combination with PD-1/PD-L1 inhibitors for the treatment of various solid tumors, including non-small cell lung cancer (NSCLC) and esophageal cancer.

Other names

anti-TIGIT monoclonal antibodya-TIGIT mAbTIGIT inhibitorTIGIT antibody